Clinical trials: Monkey Pox
Monkeypox, MPOX
Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus…
- Trial name
- NCT05784038
- Testing
- Viral genomic, Untargeted Metabolomics
- Where
- 3 sites in Brazil
- Volunteers
- 80 people
- Sponsor
- Hospital Israelita Albert Einstein
Health Volunteer
A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine
This study is a randomized, double-blind, placebo-controlled Phase I clinical trial representing the first-in-human (FIH) investigation of the Monkeypox recombinant protein vaccine JT118.
- Trial name
- NCT07495202
- Testing
- JT118 experimental group
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Shanghai JunTop Biosciences Co., LTD
Monkeypox, HIV Coinfection
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP).
- Trial name
- MASH1 (NCT05965427)
- Testing
- No intervention
- Where
- 9 sites in France, Poland and 2 more
- Volunteers
- 2,000 people
- Sponsor
- NEAT ID Foundation
Monkey Pox, Monkey Diseases
Follow-up of People at Risk of Monkeypox Infection: a Prospective Cohort Study
Since one month (first case confirmed the 05/06/2022), some cases of non-imported were reported by Portuguese and British authorities then in several Europeans countries, the US and the Canada.
- Trial name
- MonkeyVax (NCT05438953)
- Testing
- Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)
- Where
- France
- Volunteers
- 164 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mpox
Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that…
- Trial name
- MPOX CARE (NCT06887556)
- Testing
- ELISA, Lateral flow assay
- Where
- Rwanda
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
Monkeypox
Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia
Background: Mpox is a zoonotic disease caused by the mpox virus (MPXV). It has been endemic in West and Central African countries.
- Trial name
- MPOX-COL (NCT06223919)
- Testing
- LC16m8
- Where
- 3 sites in Colombia
- Volunteers
- 8,686 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Colombia
Smallpox, Cowpox
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.
A Two-Phase, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 for Injection Following Single or Multiple Doses in Healthy Subjects
- Conditions
- Smallpox, Cowpox, Monkeypox, Poxvirus Infection
- Trial name
- NCT07377175
- Testing
- BSY001 for Injection (37.5mg), BSY001 for Injection (75 mg), BSY001 for Injection (150 mg)
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Monkeypox, Monkey Pox
Clinical, Virological, Immunological, Psychosocial and Epidemiological Consequences of Human Monkeypox Virus (ProMPX)
MonkeyPox Virus Infectious Disease (MPXVID) is a viral infection caused by the monkeypox virus (MPXV) which is an orthopoxvirus that is endemic in countries in West and Central Africa.
- Trial name
- ProMPX (NCT05567939)
- Testing
- Natural course of disease
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Public Health Service of Amsterdam
Monkeypox
Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT
A cluster randomized controlled trial to determine if smallpox vaccine reduces secondary cases and symptom severity in persons exposed to mpox.
- Trial name
- SMART (NCT05745987)
- Testing
- Bavarian Nordic smallpox vaccine, Typhoid VI Polysaccharide Vaccine Injectable Solution
- Where
- 10 sites in Democratic Republic of the Congo, Nigeria and 1 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- McMaster University
Monkey Pox
Observational Mondkeypox Pregnancy Cohort
PREGMPOXCO study addresses the escalating Mpox virus (MPXV) infections among pregnant women in South Kivu, DRC following a novel MPXV sub-lineage, predominantly transmitted through heterosexual contact, stressing critical gaps in…
- Trial name
- PREGMPOXCO (NCT06442501)
- Testing
- routine care
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Robert Colebunders
Neonate, Maternal Transmission
Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC
This Phase 3 open-label study aims to assess the safety and immune response of the MVA-BN mpox vaccine when administered subcutaneously to pregnant and postpartum women in the Democratic Republic of the Congo (DRC), a population…
- Conditions
- Neonate, Maternal Transmission, Mpox, Vaccination
- Trial name
- PregInPoxVac (NCT06844500)
- Testing
- MVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP)
- Where
- Democratic Republic of the Congo
- Volunteers
- 359 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Mpox
Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo
The study Mbote-TRAXX evaluates humoral and cellular immune responses in individuals vaccinated against mpox with the MVA-BN or LC16m8 vaccine administered as part of a routine mpox vaccination campaign in Kinshasa, Democratic…
- Trial name
- MBOTE-TRAXX (NCT07499739)
- Testing
- blood sample collection
- Where
- 3 sites in Democratic Republic of the Congo
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Monkey Pox
Monkeypox ASymptomatic Shedding: Evaluation by Self-Sampling MPX-ASSESS
Monkeypox (MPX) is a viral zoonosis, caused by the Monkeypox virus (MPXV), a DNA virus that belongs to the Orthopoxvirus genus and is closely related to the variola virus, the causative agent of smallpox.
- Trial name
- MPX-Assess (NCT05443867)
- Where
- Belgium
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Vaccinia
SIGA-246 to Treat Smallpox
This study will test an experimental antiviral drug called SIGA-246 for use against the smallpox virus (variola). Although smallpox has been universally eradicated, it could possibly be brought back as a bioweapon.
- Trial name
- NCT00303225
- Testing
- Vaccine: SIGA-246
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Monkeypox
Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
This observational study has been designed to characterize humoral and cellular immune responses after vaccination against monkeypox (MKP) in HIV positive and negative individuals at high risk of MKP infection during the…
- Trial name
- NCT05562323
- Where
- 3 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
COVID-19, SARS-CoV-2 Viraemia
Neutralizing Power of Serum Antibodies - 2
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies.
- Conditions
- COVID-19, SARS-CoV-2 Viraemia, Monkey Pox, Vaccination
- Trial name
- PNAS-2 (NCT07085611)
- Testing
- Sample collection (blood and optional nasal swab)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Monkeypox
Cohort Study of Healthcare Workers Receiving Imvanex®
During an outbreak of monkeypox in the UK in 2018, a third generation smallpox vaccine, Imvanex, was used for the first time to immunise healthcare workers who had been, or were expected to be, in contact with cases of monkeypox.
- Trial name
- NCT03745131
- Testing
- Blood draw
- Where
- 5 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Public Health England
Monkey Pox
Clinical and Biological Aspects of the MONKEYPOX Disease
Monkey pox virus (MPXV), of the genus Orthopoxvirus, regularly causes epidemics in endemic areas of central and western Africa. Since January 1, 2022, cases of Monkey pox have been reported to WHO by 96 Member States in the 6 WHO…
- Trial name
- PoxVac22 (NCT05627713)
- Testing
- Blood sample collection, urine sample collection
- Where
- France
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Colorectal Cancer, Monkey Pox
FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues
Colorectal cancer tissue sections were obtained according to the inclusion criteria. The formalin was used to immersed all cancer specimens. And tissues were cut to 5 μm thickness and placed on glass slides before staining.
- Trial name
- NCT05698082
- Testing
- Immunohistochemical staining with anti-FOS
- Where
- China
- Volunteers
- 120 people
- Sponsor
- xiaoliang Huang
Monkeypox
Viral Clearance and Epidemiological Characteristics in Patients With Monkeypox
The present observational study has been designed to understand the dynamics of viral clearance amongst patients with confirmed monkeypox, by quantifying monkeypox viral load in different specimens trough time, to better inform…
- Trial name
- MoViE (NCT05476744)
- Where
- 5 sites in Spain
- Volunteers
- 77 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia